2. Characteristics of included trials (II).
| Study ID | Participants | Outcome measures | Sponsor | Country |
| Abu‐Mouch 2011 | Chronic hepatitis C genotype 1 | Sustained virological response | No information | Israel |
| Atsukawa 2016 | Chronic hepatitis C genotype 1 | Sustained virological response | No information | Japan |
| Barchetta 2016 | NAFLD | Liver steatosis, liver function | No | Italy |
| Esmat 2015 | Chronic hepatitis C genotype 4 | Sustained virological response | No information | Egypt |
| Foroughi 2016 | NAFLD | Liver steatosis, liver function | No | Iran |
| Lorvand Amiri 2016 | NAFLD | Liver function, body fat | No | Iran |
| Mobarhan 1984 | Liver cirrhosis | Bone mineral density | Yes | USA |
| Nimer 2012 | Chronic hepatitis C genotype 2 or 3 | Sustained virological response | No information | Israel |
| Pilz 2016 | Liver cirrhosis | Vitamin D status, liver function | No | Austria |
| Sharifi 2014 | NAFLD | Liver function, insulin resistance index | No | Iran |
| Shiomi 1999a | Liver cirrhosis | Bone mineral density | No information | Japan |
| Shiomi 1999b | Primary biliary cirrhosis | Bone mineral density | No information | Japan |
| Vosoghinia 2016 | Chronic hepatitis C genotype 1,2,3,4 | Early virological response | No | Iran |
| Xing 2013 | Liver transplant recipients | Acute cellular rejection rate | No | China |
| Yokoyama 2014 | Chronic hepatitis C genotype 1 | Sustained virological response | No information | Japan |
NAFLD: non‐alcoholic fatty liver disease.